RITUXAN HYCELA Drug Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Tradename: RITUXAN HYCELA
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for RITUXAN HYCELA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RITUXAN HYCELA |
Recent Clinical Trials for RITUXAN HYCELA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 2 |
| Academic and Community Cancer Research United | Phase 2 |
| National Cancer Institute (NCI) | Phase 3 |
Recent Litigation for RITUXAN HYCELA
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Janssen Biotech, Inc. v. Amgen Inc. | 2022-11-29 |
| AMGEN INC. v. APOTEX INC. | 2022-06-14 |
| Acerta Pharma B.V. v. MSN Pharmaceuticals Inc. | 2022-02-03 |
See all RITUXAN HYCELA litigation
PTAB Litigation
| Petitioner | Date |
|---|---|
| Sandoz Inc. | 2023-02-03 |
| Celltrion, Inc. et al. | 2022-02-21 |
| Fresenius Kabi USA, LLC | 2021-09-24 |
Pharmacology for RITUXAN HYCELA
| Mechanism of Action | CD20-directed Antibody Interactions |
| Established Pharmacologic Class | CD20-directed Cytolytic Antibody Endoglycosidase |
| Chemical Structure | Glycoside Hydrolases |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for RITUXAN HYCELA Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for RITUXAN HYCELA Derived from Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for RITUXAN HYCELA Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | ⤷ Try a Trial | 2032-09-12 | Patent claims search |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | ⤷ Try a Trial | 2030-06-03 | Patent claims search |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | ⤷ Try a Trial | 2028-10-22 | Patent claims search |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | ⤷ Try a Trial | 2033-03-11 | Patent claims search |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | ⤷ Try a Trial | 2021-05-01 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
